F-1/A: Phaos Technology Holdings Files Amended IPO Prospectus Amidst Significant Revenue Decline and Mounting Losses

Phaos Technology Holdings (Cayman) Limited, a microscopy solutions provider, has filed an amended F-1 registration statement for its initial public offering, revealing an 82.7% revenue decrease and a 31.5% increase in net loss for the six months ended October 31, 2024, raising substantial doubt about its ability to continue as a going concern.

Summary

• Phaos Technology Holdings (Cayman) Limited is an investment holding company incorporated in the Cayman Islands, conducting operations through its wholly-owned subsidiary in Singapore, specializing in advanced microscopy solutions using patented microsphere-assisted technology.
• The company's technology allows imaging down to 137nm, significantly surpassing traditional optical microscopes' 250nm limit, and is currently the only commercially available advanced optical microscope capable of seeing below the 200nm optical limit within a commercially viable working distance.
• Product offerings include Super-resolution imagers, Specialized microscopes, and 3-D real-time image magnifiers, complemented by proprietary in-house AI-powered software for recognition patterns in research, QA/QC, and diagnostics.
• Microscopy products contributed 99.8% and 80.9% of revenue for the six months ended October 31, 2023 and 2024, respectively.
• Revenue for the six months ended October 31, 2024, was S$63,129 (US$47,720), an 82.7% reduction from S$365,415 (US$276,217) in the same period of 2023, primarily due to reduced sales orders from largest customers and diversification efforts.
• Net loss for the six months ended October 31, 2024, increased by 31.5% to S$2,019,092 (US$1,526,234) from S$1,535,175 (US$1,160,438) in the prior year period.
• Accumulated deficit increased by 45.8% to S$9,049,158 (US$6,840,259) as of October 31, 2024, from S$6,205,397 as of October 31, 2023.
• Operating expenses increased by 8.2% to S$536,561 (US$405,587) for the six months ended October 31, 2024, driven by increased travelling and other expenses related to regional expansion and administrative activities.
• Research and Development expenses increased by 71.9% to S$149,493 (US$113,002) for the six months ended October 31, 2024, due to increased testing expenses and purchase of additional R&D equipment and resources.
• The company reported negative cash flow from operations of S$1,928,899 (US$1,458,055) for the six months ended October 31, 2024, against a cash balance of S$231,655 (US$175,108), raising substantial doubt about its ability to continue as a going concern.
• The company is offering 2,700,000 Class A Ordinary Shares, and selling shareholders are offering 900,090 Class A Ordinary Shares, with an anticipated IPO price between US$4.00 and US$5.00 per share.
• Net proceeds to the company from the offering are estimated at approximately US$11.24 million, which will be allocated to marketing (5%), product development (15%), supply chain expansion (20%), and general working capital (60%).
• The company has a dual-class share structure with Class A Ordinary Shares (1 vote per share) and Class B Ordinary Shares (20 votes per share), with Class B shares convertible to Class A, but not vice-versa.
• Beh Hook Seng, the controlling shareholder, will own approximately 65.1% of Class B Ordinary Shares, representing about 62.4% of total voting power post-offering, making the company a controlled company under NYSE American rules.

Sentiment

Score: 3

Explanation: The company presents innovative technology and ambitious growth plans, but the severe decline in recent revenue, increasing net losses, negative operating cash flow, and explicit 'going concern' doubt indicate significant financial distress and high investment risk. While the IPO aims to address liquidity, the current financial performance is very weak.

Positives

• Proprietary microsphere-assisted technology allows imaging down to 137nm, a significant competitive advantage over traditional optical microscopes (250nm limit).
• Currently the only commercially available advanced optical microscope capable of seeing below the 200nm optical limit within a commercially viable working distance.
• Integrated proprietary software with AI components enhances product performance for research, quality assurance/control (QA/QC), and diagnostics.
• Offers turn-key solutions tailored to customer needs, avoiding unnecessary expenses and providing customized computer vision implementations.
• Maintains strong and stable relationships with suppliers and customers, with top 5 customers accounting for 99.9% of revenue for the six months ended October 31, 2024.
• Experienced management team with over two decades of expertise in technology and engineering, driving expansion and operational effectiveness.
• Established sales network in Asia, with solutions sold to customers in Singapore, Indonesia, the Philippines, Malaysia, Thailand, India, China, and South Korea.
• Strategic expansion plans into Southeast Asia, Middle East, United States, and Europe through joint ventures, strategic alliances, and digital marketing.
• Ongoing product development includes improving working distance of microsphere lenses, 3D analysis solutions, fully automated zoom microscopy, and digital pathology solutions for cancer cell analysis with AI.
• Developing new AI and cloud computing capabilities for image processing, recognition, and anomaly detection to reduce human workload and reliance on human judgment.
• Achieved ISO 9001/14001/45001 certifications for quality management, environmental management, and occupational health and safety.
• Received multiple prestigious awards in 2023 and 2022, including Titan Business Award for Most Innovative Company, Stevie Award for Innovation in Technology Development, and Singapore SME500 Awards.

Negatives

• Significant revenue reduction of 82.7% for the six months ended October 31, 2024 (S$63,129) compared to the same period in 2023 (S$365,415), primarily due to reduced sales orders from largest customers.
• Net loss increased by 31.5% to S$2,019,092 (US$1,526,234) for the six months ended October 31, 2024, from S$1,535,175 in the prior year period.
• Accumulated deficit increased by 45.8% to S$9,049,158 (US$6,840,259) as of October 31, 2024.
• Incurred negative cash flow from operations of S$1,928,899 (US$1,458,055) for the six months ended October 31, 2024, against a cash balance of S$231,655 (US$175,108), raising substantial doubt about its ability to continue as a going concern.
• High customer concentration, with top 5 customers accounting for 99.9% of total revenue for the six months ended October 31, 2024, and the largest customer accounting for 60%.
• Reliance on key management personnel, particularly Mr. Andrew Yeo, with no key man life insurance policies for all such individuals.
• Susceptible to fluctuations in prices and quantities of materials and components used in manufacturing.
• Exposure to credit risks of customers, with average accounts receivable turnover days of approximately 208 days for the six months ended October 31, 2024.
• Loan to PT Neura Integrasi Solusi (S$1,582,604 or US$1,196,290 outstanding as of October 31, 2024) is at early stage of development with limited operating history and revenue, posing a risk of non-recovery.
• As a controlled company and foreign private issuer, it may choose to exempt itself from certain NYSE American corporate governance requirements, potentially affording less protection to public shareholders.
• The dual-class share structure with different voting rights (Class B shares have 20 votes per share, Class A have 1 vote) limits the ability of Class A shareholders to influence corporate matters and may discourage change of control transactions.
• The company has incurred operating losses since inception and expects to continue to incur losses and negative cash flow in the future.
• The public offering price is substantially higher than the net tangible book value per share, resulting in immediate and substantial dilution of US$4.03 per Class A Ordinary Share for new investors.

Risks

• Regional and worldwide political, regulatory, social, and economic conditions in operating and expansion jurisdictions may adversely affect business.
• Fluctuations in prices and quantity of materials and components for microscopy equipment manufacturing can negatively impact profitability.
• Major failures or malfunctions in microscopy equipment sold could adversely affect reputation and profitability.
• Significant failure or deterioration in quality control systems could materially adversely affect business and operating results.
• Breach of lease agreements could lead to significant remediation costs, fines, or compensation.
• Increased competition in the microscopy equipment sales and rental business may affect market share and growth.
• Exposure to credit risks of customers, including potential payment delays, cancellations, or defaults.
• Supply chain interruptions due to third-party logistics, component manufacturers, rising transportation expenses, or geopolitical conflicts.
• Harm from negative publicity, especially given reliance on word-of-mouth referrals and customer satisfaction.
• Inability to maintain and protect intellectual property, or third-party assertions of infringement, could harm business.
• Risks related to product recalls, which could lead to significant costs, negative publicity, and damage to reputation.
• Inability of PT Neura Integrasi Solusi to meet financial obligations or enforce rights against them could materially adversely affect results.
• An active trading market for Class A Ordinary Shares may not be established or maintained, leading to significant price fluctuations.
• Failure to maintain NYSE American listing could limit investor's ability to trade and subject the company to additional restrictions.
• Extreme volatility in stock price, potentially unrelated to underlying performance, making it difficult for investors to assess value.
• Failure to implement and maintain an effective system of internal controls and/or financial reporting could lead to inaccurate reporting or fraud.
• Immediate and substantial dilution for new investors due to the public offering price being substantially higher than net tangible book value.
• Volatility of the initial public offering price, which may not be indicative of future trading prices.
• Reliance on management's judgment for use of net proceeds, which may not produce income or increase share price.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. taxpayers, leading to adverse tax consequences.
• Controlling shareholder's substantial influence over the company, potentially misaligning with other shareholders' interests and preventing beneficial transactions.
• Reliance on controlled company and foreign private issuer exemptions from certain NYSE American corporate governance requirements, potentially affording less protection to public shareholders.
• Difficulties in protecting interests and limited ability to protect rights through U.S. courts due to incorporation under Cayman Islands law.
• Judgments obtained against the company or its auditor by shareholders may not be enforceable in certain jurisdictions.
• Exposure to risks from acts of war, terrorist attacks, epidemics, political unrest, and adverse weather conditions.
• Inadequate insurance policies to cover assets, operations, and business interruptions.
• Inability to successfully implement business strategies and future plans, including diversification and expansion initiatives.
• Potential re-occurrence or prolonged global pandemic outbreak of COVID-19 or other infectious diseases could materially and adversely affect business and operations.
• Exposure to risks arising from fluctuations in foreign currency exchange rates.
• Subject to health and safety regulations and penalties, with potential adverse effects from new and changing laws and regulations.

Future Outlook

The company expects diversification of its customer base to increase and stabilize product sales. Service revenue is anticipated to contribute a greater percentage of total revenue as the product and software range grows. The company plans to expand into new countries through joint ventures and strategic alliances, broaden its marketing approach with a shift to digital marketing in Asia and physical presence expansion into the Middle East, US, and Europe. Product development will focus on continuous improvements, new product series (e.g., for digital pathology, Optical Coherence Tomography), fully automated zoom microscopy, and advanced AI/cloud computing capabilities for image processing and anomaly detection. Calibration and certification services are aimed to be provided by Q2 2025 to generate recurring income.

Management Comments

• "We believe that this is considered by the optical industry as a super resolution optical microscopy solution."
• "We expect that the diversification of our customer base will allow us to increase and stabilize our product sales through a larger customer base and lower concentration of top customers which we are working actively to broaden."
• "As we grow our product and software range, we expect that service revenue will continue to contribute a greater percentage of our revenue going forward."
• "We believe in our strong corporate culture which emphasizes the creation of shareholder value."
• "We believe that we are well positioned to compete in the industry because of (i) our strong and stable relationships with our suppliers and customers, (ii) our experienced management team, (iii) our integrated software solutions within our product portfolio; (iv) our innovative and turn-key solutions; (v) our adaptive business model; and (vi) our reliable after-sales support."
• "We expect the decrease in government grants to continue as The Company matures and the Covid-19 pandemic impact, the impetus behind many of the grants, lessens."
• "Management has commenced a strategy to raise debt and equity. If management is unable to successfully execute this plan, there will likely be a material adverse effect on our business."
• "We are confident that increased market penetration will result in exponential revenue generation, which will further assist PT Neura's ability to pay back the loan."

Industry Context

The company operates in the microscopy equipment industry, which is described as growing and increasingly competitive. It positions itself as a provider of advanced optical microscopy solutions, particularly with its patented microsphere-assisted technology that allows imaging beyond the traditional optical limit. The company aims to capitalize on emerging growth opportunities in Southeast Asia and South Asia, and expand into the Middle East, US, and Europe. Its focus on integrating proprietary AI-powered software and offering turn-key solutions aligns with broader industry trends towards automation, data analysis, and customized solutions in precision measurement, R&D, biomedical, and manufacturing sectors. The company faces competition from larger, better-funded players like Keyence Corp., Nikon Corp., Olympus Corp., and Hirox Co. Ltd.

Comparison to Industry Standards

• The company's patented microsphere-assisted technology allows imaging down to 137nm, which is significantly beyond the 250nm limit of traditional optical microscopes, positioning it as a 'super resolution optical microscopy solution' in the optical industry.
• The company claims to be the 'only commercially available advanced optical microscope that can see below the 200nm optical limit, within a commercially viable working distance', suggesting a unique market position.
• Competitors mentioned include Keyence Corp. (TYO:6861) with its IM Series and VHX Series, Nikon Corp. (TYO:7731) with its LV Series and ECLIPSE Series, Olympus Corp. (TYO: 7733) with its MX Series, DSX Series and CX Series, and Hirox Co. Ltd with its HRX Series. The company believes its integrated software, turn-key solutions, and after-sales support provide a competitive edge against these larger players.
• The company's gross margin range of 20% to 40% for its product ranges is stated as 'priced competitively' due to macro-economic factors, implying it is within or slightly below typical industry margins for specialized equipment, but the turn-key solutions allow for higher margins.
• The loan to PT Neura Integrasi Solusi, valued at US$5 million by HIEX, indicates external validation of the potential of its biomedical scanning solutions, aligning with the growing digital healthcare technology trend.

Management Changes

Corporate Governance

Legal Proceedings

• Not a party to any significant legal proceedings in Singapore as of the date of the prospectus.
• Not aware of any legal proceedings outside of Singapore.

Related Party Transactions

• The company has entered into several shareholder loan agreements with TongHuai SG Enterprise Pte. Ltd., a major shareholder. As of October 31, 2024, the payable balance due to TongHuai SG Enterprise Pte. Ltd. was S$1,145,423 (US$865,825). These loans are interest-free, unsecured, and repayable on demand.
• On February 15, 2025, the company obtained a shareholder loan from TongHuai SG Enterprise Pte. Ltd. of S$1 million with an additional option of S$1 million.
• Chua Jun Hao, David, a selling shareholder, provided a personal guarantee with respect to loans taken by Phaos Technology Pte. Ltd. as a prior shareholder of TongHuai SG Enterprise Pte. Ltd.

Stakeholder Impact

• **Shareholders (Existing & New):** Existing shareholders will experience significant dilution (US$4.03 per Class A Ordinary Share) due to the IPO price being substantially higher than the net tangible book value. New investors face high risk due to the company's early revenue stage, operating losses, negative cash flow, and going concern doubt. The dual-class share structure limits voting power for Class A shareholders. The success of the IPO and future capital raises is crucial for the company's continued operation and potential return on investment.
• **Employees:** The company plans to add personnel in sales, marketing, R&D, and operations, indicating potential job growth. An employee share incentive plan (2025 ESIP) is intended to incentivize performance and align interests, potentially benefiting employees. However, the company's 'going concern' doubt poses a risk to job security if additional capital is not secured.
• **Customers:** The company's focus on expanding its product range, improving existing products, and providing turn-key solutions aims to better meet diverse customer needs. Strengthening the distribution network and after-sales support is intended to enhance customer satisfaction. However, supply chain interruptions and potential equipment malfunctions could negatively impact customer experience.
• **Suppliers:** The company emphasizes strong and stable relationships with key suppliers. However, fluctuations in material prices and quantities, and supply chain disruptions, could affect the company's ability to procure components, potentially impacting supplier relationships.
• **Creditors:** The company has significant outstanding loans and a negative cash flow from operations, raising concerns about its ability to meet obligations. The subordination of shareholder loans to bank loans provides some protection to bank creditors. The loan to PT Neura Integrasi Solusi also represents a credit risk for the company itself.

Next Steps

• Complete the initial public offering and list Class A Ordinary Shares on the NYSE American under the symbol POAS.
• Utilize IPO net proceeds for marketing and promotion campaigns (5%), product development (15%), supply chain expansion (20%), and general working capital/corporate purposes (60%).
• Continue to diversify customer base to increase and stabilize product sales.
• Grow service revenue as product and software range expands.
• Strategically expand into new countries (Indonesia, Thailand, Philippines, Vietnam, Middle East, US, Europe) through joint ventures, strategic alliances, and marketing efforts.
• Continue product development, including improving microsphere-assisted microscope working distance, 3D analysis solutions, fully automated zoom microscopy, and digital pathology solutions for cancer cell analysis.
• Further develop AI and cloud computing capabilities for image processing, recognition, and anomaly detection.
• Provide calibration and certification services to existing and new customers by Q2 2025 to generate recurring income.
• Hire more qualified accounting personnel and implement regular U.S. GAAP and SEC reporting training programs to strengthen financial reporting and internal controls.
• Engage an external consulting firm to assist with Sarbanes-Oxley compliance and internal control improvement.
• Work actively to broaden customer base and lower concentration of top customers.

Key Dates

Recommendation

Keywords

Microscopy, Super-resolution imaging, Optical microscope, AI software, Precision measurement, Magnification, Biomedical, Semiconductors, Manufacturing, Research & Development, QA/QC, Diagnostics, IPO, F-1/A, SEC filing, Cayman Islands, Singapore, Vietnam, Southeast Asia, Patented technology, Dual-class shares, Controlled company, Foreign private issuer